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Objectives: Prevalence of diabetes mellitus is increasing globally in most developed 
and developing countries and Dipeptidyl peptidase-4 inhibitors (Gliptins) are recently 
introduced class of drugs for type 2 diabetes mellitus which shows good glycemic 
control. It is a prospective interventional pilot study aimed to determine the efficacy 
of add-on vildagliptin therapy to metformin in type 2 diabetes mellitus patients for 
a period of 6 months in south Indian resource limited settings. MethOds: A total 
of 185 patients were enrolled into the study. The study subjects were assigned into 
three groups based on their existing treatment (initiated within one month) i.e., group 
I (vildagliptin and metformin), group II (vildagliptin alone) and group III (metformin 
alone). They were also assessed for baseline demographic characteristics. Medication 
adherence was measured to ensure that patients are complies with the treatment. 
The clinical endpoint was estimated by using various variables like quality of life and 
other clinical endpoints such as RBS, PPBS after three months of specific treatment 
through direct interview and by referring the medical case records. Results: The 
results show that there is no significant difference in individual groups in terms of 
demographic characteristics. (P > 0.01). And all the present study subjects are found to 
have more than 90 % of medication adherence. We observed high level of significant 
improvement in group I (93.18±3.76) subjects whereas low level of improvement in 
group III subjects (90.4±4.13) after the relevant treatment (P = 0.003). Group I subjects 
are also found to have good glycaemic control (RBS, FBS and PPBS) than any other 
treatment groups P< 0.01). cOnclusiOns: Add on vildagliptin therapy to metformin 
might improve the quality of life of type 2 diabetes mellitus patients and might be 
useful to bring the glycemic levels under control in type 2 diabetic patients in South 
Indian resource limited settings.
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Objectives: To evaluate the accuracy of different blood glucose determination meth-
ods, and provide a theoretical basis for governments to determine the mainstream 
glucose detection methods. MethOds: The MEDLINE, EMBASE, EBM REVIEWS, CBM, 
CNKI, Wanfang, Google academic search et al were were retrieved for literatures col-
lection, literature quality evaluation was implemented by using QUADAS criteria, 
meta-analysis was carried out using Stata11.0 and heterogeneity test and sensitivity 
analysis was implemented. Results: 20 studies were included, which contained a 
total of 2681 cases of patients. Meta analysis showed that values measured by the 
dry chemical method were significantly higher than glucose oxidase method, and 
no significant differences was found with the hexokinase method, no significant 
differences was yet found between the electrode method with enzyme method, the 
MD (95%CI) were 0.31 (0.09, 0.53), -0.51 (-0.14, 1.17) and -0.13, (-0.27, 0.02) respectively. 
Sensitivity analysis of the model, the sample source, research population, equip-
ment and countries was carried out and conclusion was found no change between 
the methods. cOnclusiOns: there was significant difference between different 
blood glucose detection methods; application of dry chemical measurement results 
should be cautious, we recommend using the glucose oxidase or diagnosis hexoki-
nase method.
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Objectives: Hypothroidism is treated by replacement therapy of levothyroxine in 
allopathic system of medicine needs to be taken through out life time. In Ayurveda 
an ethnic system of Indian medicine has a remedy based on the drugs of natural ori-
gin which showes improved thyroid function. In this study the patients are treated 
for Hypothroidism with combination of two proprietary medicines (herbotrim and 
Muniprabha) of Muniyal Ayurveda Pharmacy, Manipal. MethOds: Thirty cases 
Hypothyroidism are selected from Inpatients and Out patients of Muniyal Ayurveda 
Hospital, Manipal after obtaining the consent of the patients. The study was 
approved by intitutional ethics committe. The study design consited of observation 
before and after teatment with Herbotrim 2-0-2 (2 BID) with water and Muniprabha 
1-1-1 (1TID) with water, tablets along with concomitant medicines for a period of 
3 months. The subjective Obesity, Brady cardia, Somnolence, Slow mentationand 
objective criteria of assessment were T3, T4, TSH, Hb% and cholesterol. Results: 
The Mean palsma T3 (mcg/dl) levels were 33.4 to 105.4, T4 (mcg/dl) levels were 2.38 
to 11.36 and TSH (micro IU/ml) levels were109.4 to 6.63. The hemoglobin (g%) levels 
were increased from 10.05 to 12.24 and serum cholesterol (mg%) leveles were drop-
ded from 280 to 158.9. cOnclusiOns: Considerable improvement was observed in 
both subjective and objective criteria of assessment. There was decrease in subjec-
tive criteria like – Obesity, Brady cardia, Somnolence, Slow mentation, etc. There 
was increase in T3 and T4, and nd Hb%. The decrease in TSH and cholesterol with 
Herbotrim and Muniprabha in Hypothyroidism patients.
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Objectives: To examine the association between incretin-based therapies and 
the risk of pancreatitis. MethOds: We searched Medline, Embase, CENTRAL and 
ClinicalTrials.gov to identify randomized controlled trials (RCTs), non-randomized 
clinical trials, cohort studies, and case-control studies of adults with type 2 diabe-
tes mellitus that compared glucagon-like peptide-1 (GLP-1) receptor agonists or 
dipeptidyl peptidase-4 (DPP-4) inhibitors against placebo or active anti-diabetic 
medications. Trained reviewers, working in pairs, independently screened for eli-
gible studies, assessed risk of bias, and extracted data. Results: We included 59 
studies (n= 348,624), consisting of 55 RCTs (n= 33,350) and 4 observational studies 
(n= 315,274). Pooled estimates of 55 RCTs (at low or moderate risk of bias involv-
ing 37 pancreatitis events, raw event rate 0.11%) did not suggest increased risk 
of pancreatitis between incretin agents versus control (Peto OR 1.11, 95% CI 0.57 
to 2.17). Estimates by type of incretin agents suggested similar results (GLP-1 
agonists vs. control: OR 1.05, 95% CI 0.37 to 2.94; DPP-4 inhibitors vs. control: 
OR 1.06, 95% CI 0.46 to 2.45). Three retrospective cohort studies (moderate to high 
risk of bias involving 1466 pancreatitis events, raw event rate 0.47%) also did not 
suggest increased risk of pancreatitis associated with either exenatide (adjusted 
OR 0.93, 95% CI 0.63 to 1.36 in one study, adjusted hazard ratio (HR) 0.9, 95% CI 
0.6 to 1.5 in another) or sitagliptin (adjusted HR 1.0, 95% CI 0.7 to 1.3). However, 
a matched case-control study with moderate risk of bias suggested that the use 
of either sitagliptin or exenatide was associated with increased odds of acute 
pancreatitis (adjusted OR 2.07, 95% CI, 1.36 to 3.13). cOnclusiOns: The available 
evidence suggests that the risk of pancreatitis in patients using incretin agents 
is very low, and does not support for the hypothesis that incretins increase the 
risk of pancreatitis.
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Objectives: This study evaluated the effect of anti-thyroid drugs and thyroid-
ectomy on response of hyperthyroidism to fixed doses of Radioactive Iodine 
Therapy (RAI) and the incidence of hypothyroidism at 6months post RAI ther-
apy. MethOds: A retrospective review of the medical records of 42 hyperthyroid 
patients treated with radioiodine to evaluate response rate of hyperthyroidism 
to two fixed dose regimens of 370 MBq (10 mCi) and 555 MBq (15 mCi) RAI ther-
apy was carried out. The impacts of thyroidectomy and ant-thyroid drug pre-
treatment were documented. The treatment goal is to cure hyperthyroidism by 
rendering the patient either euthyroid or hypothyroid, within 6months of single 
dose of 370 MBq (10 mCi) or 555 MBq (15 mCi) RAI therapy. Statistical analysis was 
with SPSS version 15.0 and the level of statistical significance was taken as P < 
0.05. Results: The response (i.e. hypothyroid and euthyroid) at 6months post RAI 
for both doses of radioiodine was 71.4%, and after re-treatment of 7 patients who 
were earlier hyperthyroid after 6months, the response rate soared to 95.2%. The 
incidence of hypothyroidism (TSH > 6.1 mIU/L) was 47.6% with patients who had 
received 370 MBq (10 mCi) and 38.1% with those that received 555 MBq (15 mCi) 
radioiodine therapy. The use of anti-thyroid drugs (carbimazole or methima-
zole only) as pre-treatment increased response to RAI; Propylthiouracil however 
blocked response to RAI therapy in one patient Thyroidectomy, either total or 
subtotal, increased the response to RAI treatment. cOnclusiOns: Radioactive 
iodine is highly effective for the treatment of Graves’ hyperthyroidism, with a very 
high cure rate. Pretreatment with some anti-thyroid drugs protects against wors-
ening of thyrotoxicosis after radioiodine and increases response to RAI therapy. 
Thyroidectomy increases the response to RAI treatment. However, the incidence 
of hypothyroidism should be anticipated and well prepared for as part of the 
treatment protocol.
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Objectives: To systematically review the effectiveness and safety of premixed 
insulin lispro and insulin glargine in type 2 diabetes. MethOds: Such databases as 
PubMed, EMBASE, The Cochrane Library, ClinicalTrials.gov, CBM, CNKI and WanFang 
were searched for relevant studies from inception to October, 2013. Two review-
ers independently screened studies according to exclusion and inclusion criteria, 
extracted data and assessed the methodological quality. Then, meta-analysis was 
performed using RevMan 5.2 software. Results: 13 RCTs involving 4267 patients 
were included. The results of meta-analysis showed that, compared to insulin 
glargine, premixed insulin lispro effectively improved HbA1c levels [WMD= -0.18, 
95%CI (-0.33, -0.02), P= 0.03(parallel trials), WMD= -0.38,95%CI(-0.52,-0.24), P< 0.00001 
(cross-over trials)]. However, insulin glargine effectively improved FPG levels 
[WMD= 0.82,95%CI(0.65, 0.99), P< 0.00001 (parallel trials)]; WMD= 0.64,95%CI(0.26, 
1.02), P= 0.0009 (cross-over trials)], weight gain[WMD= 0.93, 95%CI(0.31,1.56), 
P= 0.003 (parallel trials); WMD= 0.74, 95%CI(0.19,1.29), P= 0.009(cross-over trials)] 
and decrease hypoglycemia incidence[OR= 1.26, 95%CI(1.10, 1.45), P= 0,0007(paral-
lel trials), OR= 2.24, 95%CI(1.45, 3.46), P= 0.0003(cross-over trials)]. cOnclusiOns: 
: Premixed insulin lispro and insulin glargine have different advantages in clinical 
efficacy. Doctors should select the appropriate insulin treatment according to the 
patient’s health condition and efficacy target.
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Objectives: Bariatric surgery has been recommended as an effective treatment for 
overweight or obese patients with type 2 diabetes mellitus. The long-term follow up 
of such patients, however, has been limited. We performed a systematic review and 
meta-analyses to evaluate the long-term effect of bariatric surgery on patients with 
type 2 diabetes. MethOds: We searched PubMed, EMbase, and Cochrane Central 
Register of Controlled Trials up to September 2013. Trained reviewers, working in 
pairs, independently screened for eligible studies and extracted data. We pooled the 
data by using random-effects meta-analysis; qualitative description was applied 
for the data not available for pooling. We conducted pre-specified subgroup analy-
ses. Results: We included 25 studies (n= 23,628), consisting of 8 cohort studies with 
17407 patients (moderate or high risk of bias) and 17 non-controlled follow up stud-
ies with 6221 patients (high risk of bias). At baseline, the mean age of 48.5 years (69% 
were female), mean body mass index (BMI) was 45 kg/m2, 67% of patients received 
oral antidiabetic drug prior to surgery. 2.6% of patients (130/4950) died in the surgical 
group. Improvement on cardiovascular complications, nephropathy and quality of 
life was observed. BMI (-13.13 kg/m2[-17.66,-9.07]), Fasting Plasma Glucose (-59.74 
mg/dl [-74.59,-44.89]), and hemoglobin A1c (-1.83% [-2.4,-1.25]) declined significantly 
postoperatively. 67.1% of patients were in remission; diabetes was improved or 
resolved in 89.2% of patients. Subgroup analysis for alterative surgical procedures, 
length of follow up and the methods of data collection suggested no significant 
different. cOnclusiOns: Bariatric surgery should be considered as a long-lasting 
and effective treatment for patients with type 2 diabetes. However, our results are 
based on a small number studies with low quality, additional carefully designed 
studies on mortality, cardiovascular events and adverse events may provide further 
clarification.
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Objectives: To explore the impact of diabetes on mortality in inpatients from 
Medical Department in a Chinese tertiary hospital. MethOds: The data source 
was based on the electronic medical records (EMRs) database of West China 
Hospital. We collected diabetic and non-diabetic patients, in a ratio of 1:3,who 
were hospitalized from January 2009 to December 2012. The non-diabetic patients 
were chosen immediately after a diabetic patient was selected based on sequential 
unique hospitalized ID. Patients from medical department were chosen for analy-
sis. We collected information regarding patient demographics, diagnoses, prescrip-
tions, laboratory tests and health care resource utilization use. The ascertainment 
of diabetes and common co-morbidities (e.g.COPD) was based on ICD-10 code. 
Using in-hospital mortality as an outcome, we conducted multivariable logistic 
regression to explore the association of diabetes with mortality, after controlling 
for the influence of common co-morbidities of diabetes – which were considered 
important confounders - age, gender, smoking and alcohol use. Results: The 
retrospective analysis included a total of 32,052 patients with diabetes and 66,087 
patients without. The median ages were 66(IQR 56-74) and 52(IQR 39-65) in diabetic 
and non-diabetic group, respectively. And thus 19,659(61%) and 35,214(53%) were 
males, respectively. Multivariable logistic regression showed that patients with dia-
betes had an increased risk of mortality (adjusted odds ratio, AOR:1.17; 95%CI:1.03-
1.34) after controlling for common co-morbid conditions, including ischemic 
heart disease (AOR:1.56; 95%CI:1.32-1.85), chronic obstructive pulmonary disease 
(AOR:1.84; 95%CI: 1.55-2.19), kidney failure (AOR:4.75; 95%CI: 4.07-5.55), hepatic 
fibrosis and cirrhosis (AOR:4.02; 95%CI: 3.21-5.04), malignances (AOR:3.03; 95%CI: 
2.65-3.46) and depressive episode (AOR:1.82; 95%CI: 0.92-3.58). cOnclusiOns: 
Diabetes appears to be independently associated with increased risk of death in 
hospitalized patients in the medical departments. Nonetheless, this finding may 
be limited due to the control patient selection method (not randomly selected). 
Thus, the resulting association of diabetes and other co-morbid conditions with 
in-hospital death may be of limited generalizability.
PDB12
hyDrOxyEthyl starch anD hOsPitalizED MOrtality in icu PatiEnts 
with DiaBEtEs: DataBasE stuDy frOM a chinEsE tErtiary hOsPital
Li S, Yu C, Li Y, Zhang R, Ma Y, Hou Q, Li Q, Zheng T, Wang M, Su N, Li N, Liu G, Huang Y, Sun 
X, Tian H
West China Hospital, Sichuan University, Chengdu, China
Objectives: To explore whether HES is independently associated with hospitalized 
mortality in ICU patients with diabetes from a Chinese tertiary hospital. MethOds: 
The retrospective cohort was from the electronic medical records (EMRs) database 
of West China Hospital from December 2010 to December 2012, which consisted of 
inpatients who were ever admitted in ICU department and had a discharge diagnosis 
of diabetes. Demographic characteristics, diagnoses, prescriptions, and laboratory 
tests were extracted. Ischemic heart diseases (IHD) and chronic renal failure (CRF) 
were extracted from discharging diagnoses according to ICD-10. High blood glucose 
was defined as the blood glucose higher than 7.8 mmol/L according to recommen-
dation from ENDO society when the patient was first admitted to hospital. Acute 
kidney injury (AKI) during hospitalization was defined as at least 1.5 fold increase 
of serum creatinine from baseline, according to KDIGO AKI guideline. Outcome vari-
able was the mortality during the hospitalization. Multivariate logistic regression 
model was used to explore the association of use of HES with mortality, adjusting 
for age, gender and above factors. Results: A total of 1,036 ICU patients with dia-
betes were identified in the database with a median age of 65(IQR 25-73) years old. 
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Objectives: To evaluate the prevalence of insulin injection-related lipohyper-
trophy (LH), a common complication of insulin therapy, associated risk factors, 
and to characterize the clinical and economic burdens of LH. Secondary objec-
tives will investigate the relationship between LH and HbA1c, total daily insulin 
dose, injection education, and reimbursement status among diabetic patients in 
China. MethOds: A descriptive, non-interventional, cross-sectional study was 
conducted among 400 diabetic patients from outpatient endocrinology depart-
ments in 4 cities, with and without insulin pen needle reimbursement. Eligible 
subjects were: ages 18-80, BMI ≥ 18.5 kg/m2, using insulin by pen injection currently 
and for ≥ one year continuously, with the ability to comprehend study procedures. 
Enrolled subjects 1) completed a questionnaire for socio-demographics, medical 
history, self-reported disease management as well as health resource utilization 
and work productivity, 2) underwent a structured physical examination, and 3) 
had HbA1c evaluated. The prevalence of LH was described by percentage and 
95% confidence interval. Logistic regression and log-linear analysis were applied 
to determine risk factors and the relationship between LH, HbA1c and insulin 
dose. Differences in insulin consumption and general health resource utilization 
were calculated between those with and without LH, and those with or without 
pen needle reimbursement. Results: Results expected: 1) Prevalence of insulin 
injection-related lipohypertrophy among patients in China using pen devices. 2) 
Risk factors for LH including socio-demographic characteristics, economic issues, 
and insulin injection-related factors. 3) Relationship between LH and HbA1c, hypo-
glycemia, and total daily insulin dose. 4) Economic burden of LH in the Chinese 
diabetes population. cOnclusiOns: Given the potential implications of LH for 
the diabetic population and for the Chinese health care system, we hope to bring 
awareness of the true magnitude of this condition.
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Objectives: Traditional medicines are valuable in management of chronic 
diseases like DM type 2. The Ayurvedic classical formulation Khadira kramuka 
kashaya(KKK) and Shilajatu(SHJ) are found to be clinically effective in DM type 
2. In this study, the clinical effect of the combination of formulations was stud-
ied. MethOds: The combined formulation (KKK+SHJ) was administered to 30 
patients whose base line data on blood sugar, HbA1C were recorded for 45 days. 
Apart from this, the patients feedback on urination frequency and quantity, 
Neuropathic symptoms, exhaustion, polydipsia, polyphagia, glycosuria and per-
spiration as per Ayurveda QOL were carried out once in 15 days . Results: the 
Mean for 30 patients FBS, PPBS (mg/dl) and HbA1C on day1, day 15, day 30 and 
day 45 were given in order. QOL data on day 1 and day 45 were given. The mean 
for 30 patients on FBS (mg/dl) on day1, day 15, day 45 - 136.2, 132.4, 30 129.5, 127.8; 
On PPBS (mg/dl) day1, day 15, day – 224.36, 223.62, 220.41, 218.83 ; HbA1C (%) on 
day1, day 15, day 45 – 7.84, 7.82, 7.79, 7.73. Overall assessment of Ayurveda QOL 
showed mild to moderate efficacy. cOnclusiOns: The classical combination of 
KKK and SHJ was found to be clinically effective along with improvement in QOL 
Ayurveda parameters.
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Objectives: Fuelled by dietary changes, increased sedentary lifestyles, and 
greater urbanisation in the Asia-Pacific region, there has been an increase in the 
number of people suffering from diabetes. Understanding the impact of ethnicity 
on the efficacy and safety of anti-diabetes drugs is necessary to optimise drug 
development strategies and shorten the time lag between drug approval in the 
West and in Asia. The purpose of this study was to examine the role of ethnicity 
on treatment outcomes in diabetes clinical trials, using liraglutide as an exam-
ple. MethOds: Targeted searches were performed in PubMed and clinicaltrials.
gov to identify relevant studies. To be included in our analysis the study had to: 
be a completed double-blind phase 3 clinical trial of liraglutide; include patients 
with type 2 diabetes and report Δ HbA1c as an outcome. The included studies were 
divided by population ethnicity, followed by subsequent extraction of relevant 
baseline characteristics and outcomes. Results: Nine Asian and eight non-Asian 
studies satisfied all inclusion criteria. Asian study populations tended to have a 
lower body mass index than their non-Asian comparators, which was reflected 
by the lower treatment dosages. Moreover, there was a trend towards longer 
duration of disease in Asians, although not statistically significant (p= 0.5636). 
Substantial heterogeneity was observed between the clinical trial designs, includ-
ing variable treatment durations, choice of comparator drugs, and the use of 
mono- or combination therapy. As a result, it was not possible to compare the 
clinical outcomes between Asian and non-Asian populations. cOnclusiOns: 
Clear differences between Asian and non-Asian studies highlight the need for 
improved standardisation of clinical trial designs to enable the investigation of 
the impact of ethnicity on efficacy and safety results from clinical trials. Further 
research into other drugs and disease areas is required to more fully understand 
this topic.
